Pearce IP provides weekly reports on global biosimilars activities in the Pearce IP BioBlast®. Significant biosimilar activities for the week ending 18 July are set out below…
Pearce IP BioBlast® for the week ending 18 July 2025
read more
DRUG ADVERTISING IN NEW ZEALAND – NZ allows advertising of unapproved drugs… soon
A new development in New Zealand will provide an option for a faster route to judgment in patent and other intellectual property litigation. From 1 October 2025, a Commercial…
Pearce IP BioBlast® for the week ending 11 July 2025
Pearce IP provides weekly reports on global biosimilars activities in the Pearce IP BioBlast®. Significant biosimilar activities for the week ending 11 July are set out below…
Pearce IP BioBlast® for the week ending 4 July 2025
Pearce IP provides weekly reports on global biosimilars activities in the Pearce IP BioBlast®. Significant biosimilar activities for the week ending 4 July are set out below…
Extended Release, Expeditious Rejection: Federal Court Invalidates Sun Pharma’s Aripiprazole PTE
On 5 February 2025, Justice Downes of the Federal Court of Australia delivered her decision in the dispute between Otsuka Japan and its licensees (Lundbeck A/S and Australia and Otsuka Australia) (collectively…
THE HIGH COURT COMMERCIAL LIST – A new, faster route to judgment for patent litigation in New Zealand
A new development in New Zealand will provide an option for a faster route to judgment in patent and other intellectual property litigation. From 1 October 2025, a Commercial…
Pearce IP BioBlast® for the week ending 27 June 2025
Pearce IP provides weekly reports on global biosimilars activities in the Pearce IP BioBlast®. Significant biosimilar activities for the week ending 27 June are set out below…
Pearce IP BioBlast® for the week ending 20 June 2025
Pearce IP provides weekly reports on global biosimilars activities in the Pearce IP BioBlast®. Significant biosimilar activities for the week ending 20 June are set out below…
Australasian Lawyer and NZ Lawyer Rank Pearce IP as 2025 Top Specialist Firm
Pearce IP and 7 of its leaders have been ranked in Australia and New Zealand for patent litigation and prosecution by IAM Patent 1000 for 2025.
Pearce IP Leaders Recognised in WIPR Leaders 2025
Pearce IP and 7 of its leaders have been ranked in Australia and New Zealand for patent litigation and prosecution by IAM Patent 1000 for 2025.
Pearce IP is the DEI: Outstanding Firm – 2025 Chambers Asia-Pacific & Greater China
Pearce IP and 7 of its leaders have been ranked in Australia and New Zealand for patent litigation and prosecution by IAM Patent 1000 for 2025.
Pearce IP BioBlast® for the week ending 13 June 2025
Pearce IP provides weekly reports on global biosimilars activities in the Pearce IP BioBlast®. Significant biosimilar activities for the week ending 13 June are set out below…
Pearce IP Ranked by MIP for Trade Mark Prosecution 2025
Pearce IP and 7 of its leaders have been ranked in Australia and New Zealand for patent litigation and prosecution by IAM Patent 1000 for 2025.
6 Pearce IP Lawyers/Attorneys Recognised by 2025 MIP IP STARS
We are thrilled to announce that 6 Pearce IP patent professionals have again been recognised by Managing IP in the 2025 MIP IP STARS, a leading global guide to the top intellectual property firms and practitioners.
IAM Patent 1000 Honours Pearce IP & 6 Leaders for 2025
Pearce IP and 7 of its leaders have been ranked in Australia and New Zealand for patent litigation and prosecution by IAM Patent 1000 for 2025.
Pearce IP BioBlast® for the week ending 6 June 2025
Pearce IP provides weekly reports on global biosimilars activities in the Pearce IP BioBlast®. Significant biosimilar activities for the week ending 6 June are set out below…
Pearce IP BioBlast® for the fortnight ending 30 May 2025
Pearce IP provides weekly reports on global biosimilars activities in the Pearce IP BioBlast®. Significant biosimilar activities for the week ending 30 May are set out below…
Pearce IP Recognised in Best Law Firms 2026!
Pearce IP Recognised in Best Law Firms 2026!
Scanning for Justice: Hytera’s Radio Technology Appeal Falls on Deaf Ears
The Full Court of the Federal Court has delivered judgment in the proceedings between Motorola Solutions Inc (Motorola) and Hytera Communications Corporation Ltd (Hytera), in their ongoing…
Pearce IP BioBlast® for the week ending 16 May 2025
Pearce IP provides weekly reports on global biosimilars activities in the Pearce IP BioBlast®. Significant biosimilar activities for the week ending 16 May are set out below…
Pearce IP BioBlast® for the week ending 9 May 2025
Pearce IP provides weekly reports on global biosimilars activities in the Pearce IP BioBlast®. Significant biosimilar activities for the week ending 9 May are set out below…
Naomi Pearce named finalist in two categories at the 2025 Partner of the Year Awards
Pearce IP’s Founder and CEO Naomi Pearce is a finalist in two categories of the 2025 Lawyers Weekly Partner of the Year Awards: Senior Partner of the Year – 15 Years or More...
Pearce IP BioBlast® for the week ending 2 May 2025
Pearce IP provides weekly reports on global biosimilars activities in the Pearce IP BioBlast®. Significant biosimilar activities for the week ending 2 May are set out below…
Pearce IP Strengthens New Zealand Team & Welcomes Executive Sally Paterson
Sally Paterson Joins Pearce IP – Executive Lawyer, Patent and Trade Mark Attorney
Recent BioBlast® Updates
Get our Pearce IP Blogs & BioBlast® sent directly to your inbox
Subscribe to our Pearce IP Blogs and BioBlast® to receive our updates via email.